Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03739840 · ClinicalTrials.gov registry record · Phase 3
A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy
A Phase 3 study, sponsored by UCB Biopharma SRL.
- Terminated
- Registry status
- Phase 3
- Development phase
- 232
- Enrollment target
NCT03739840 is a Phase 3 study that was terminated before completion, run by UCB Biopharma SRL. The registered enrollment target is 232 participants.
The verdict
NCT03739840, a Phase 3 study, was terminated before completion, sponsored by UCB Biopharma SRL.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 232 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy, safety and tolerability of the 3 selected dose regimens of padsevonil (PSL) administered concomitantly with up to 3 anti-epileptic drugs (AEDs) compared with placebo for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy.
Interventions
- DRUG Placebo
- DRUG Padsevonil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2019-03-06 |
| Est. Completion | 2020-09-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03739840
The ClinicalTrials.gov registry entry for NCT03739840 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03739840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03739840 about?
NCT03739840 is a clinical study titled "A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy". The purpose of the study is to evaluate the efficacy, safety and tolerability of the 3 selected dose regimens of padsevonil (PSL) administered concomitantly with up to 3 anti-epileptic drugs (AEDs) compared with placebo for treatment of observable focal-onset seizures in subjects with drug-resistant...
What is the current status of trial NCT03739840?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 232 participants. The study started on 2019-03-06. Estimated completion is 2020-09-28.
What interventions are being tested in trial NCT03739840?
The interventions under investigation include: Placebo (DRUG), Padsevonil (DRUG).
Who is sponsoring clinical trial NCT03739840?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.